Abstract: The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Type:
Application
Filed:
March 20, 2009
Publication date:
September 24, 2009
Applicant:
FOREST LABORATORIES HOLDINGS LIMITED
Inventors:
Kumar Sundaresan, Sandeep N. Raikar, Srinivasa Raju Sammeta, Ganesh Prabhu, Hosahalli S. Subramanya, Alexander Bischoff
Abstract: The present invention relates to piperidine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Abstract: The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Abstract: The present invention relates to a method of treating a central nervous system disorder, such as a mood disorder (e.g., major depressive disorder) or an anxiety disorder (e.g., general anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder) with a low dose combination of escitalopram and bupropion.
Abstract: Methods for the synthesis of heterocyclic compounds including N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide and pharmaceutically acceptable salts thereof.
Type:
Application
Filed:
December 24, 2008
Publication date:
July 30, 2009
Applicant:
FOREST LABORATORIES HOLDINGS LIMITED
Inventors:
Gian-Luca Araldi, Melanie Ronsheim, Nhut Diep, Shao Hong Zhou
Abstract: The present invention relates to compounds of formula I, II, III or IV: wherein R1-R4, R7-R10, R13-R17 and R20-R24 are as described herein. The compounds are active as cannabinoid receptor ligands, e.g., CB2 ligands. Methods of preparing the compounds, compositions containing the compounds and methods of treatment using the compounds are also disclosed.
Type:
Grant
Filed:
August 27, 2007
Date of Patent:
July 21, 2009
Assignee:
Forest Laboratories Holding Limited
Inventors:
Gian-Luca Araldi, Matthew Ronsheim, Nhut K. Diep
Abstract: The present invention provides methods of treating sexual dysfunction. The methods include administering an effective amount of nebivolol, or a pharmaceutically acceptable salt thereof, alone or in combination with a second active agent e.g. a PDE-5 inhibitor, such as sildenafil citrate. The methods of the present invention are particularly suited to the treatment of erectile dysfunction and female sexual arousal disorder.
Type:
Application
Filed:
January 14, 2009
Publication date:
July 16, 2009
Applicant:
FOREST LABORATORIES HOLDINGS LIMITED
Inventors:
Inigo Saenz de Tejada, Javier Angulo, Sandeep Gupta
Abstract: Methods for the synthesis of heterocyclic compounds including N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide and pharmaceutically acceptable salts thereof.
Type:
Application
Filed:
February 12, 2009
Publication date:
June 4, 2009
Applicant:
FOREST LABORATORIES HOLDINGS LIMITED
Inventors:
Gian-Luca Araldi, Melanie Ronsheim, Nhut Diep, Shao Hong Zhou
Abstract: Methods for the synthesis of heterocyclic compounds including N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
July 3, 2007
Date of Patent:
March 31, 2009
Assignee:
Forest Laboratories Holdings Limited
Inventors:
Gian-Luca Araldi, Melanie Ronsheim, Nhut Diep, Shao Hong Zhou
Abstract: The present invention relates to new dosage forms of cephem compounds, useful for the treatment of bacterial infections. The dosage forms are stable, exhibit enhanced solubility, and are particularly well suited for, e.g., parenteral administration.
Abstract: The present invention relates to pyridoimidazole derivatives that act as cannabinoid receptor ligands, e.g., CB2 ligands. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Abstract: The present invention relates to pharmaceutical compositions containing dopamine receptor ligands and selective serotonin reuptake inhibitors and to methods of treating disorders such as schizophrenia, major depressive disorder and bipolar depression using combinations of dopamine receptor ligands and selective serotonin reuptake inhibitors. The present invention also relates to methods of treating depression using dopamine receptor ligands.
Abstract: The present invention relates to novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives and, more particularly, to novel solvate and crystalline forms of trans-1{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea hydrochloride. Processes for the preparation of these forms, compositions containing these forms, and methods of use thereof are also described.
Type:
Application
Filed:
May 9, 2008
Publication date:
January 29, 2009
Applicant:
FOREST LABORATORIES HOLDINGS LIMITED
Inventors:
Xiangmin Liao, Haijian Zhu, Andreas Grill
Abstract: The present invention relates to reducing carbohydrate derivatives of adamantane amines of Formula A or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R1, R2, R3, and R4 are together or separately H, F, methyl or lower alkyl, alkenyl, or alkynyl groups, and Z is derived from a mono-, di-, oligo-, or poly-saccharide that originally had an aldehyde carbonyl group. The present invention also relates to processes for the preparation of such adamantane amine derivatives, and uses of such derivatives. The compounds of the present invention are useful in the treatment of infections caused by Gram positive or Gram negative bacteria.
Type:
Application
Filed:
June 24, 2008
Publication date:
December 4, 2008
Applicant:
FOREST LABORATORIES HOLDINGS LIMITED
Inventors:
Sebastian P. Assenza, Nanzhu Shen, Salvatore Iacono, Yuriy B. Kalyan, Peter Viski, Matthew Ronsheim
Abstract: The present invention relates to bioavailable pharmaceutical formulations of heterocyclic compounds, such as such as N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide (oglemilast) and pharmaceutically acceptable salts thereof, to processes for their preparation and to methods of treatment using the same. The present invention also relates to substantially pure amorphous forms of heterocyclic compounds, such as oglemilast. The invention is particularly directed to bioavailable pharmaceutical oral dosage forms containing amorphous oglemilast.
Type:
Application
Filed:
February 8, 2008
Publication date:
August 14, 2008
Applicant:
Forest Laboratories Holdings Limited
Inventors:
Mahendra G. DEDHIYA, Rahul Surana, Suneel K. Rastogi, Anil Chhetrry
Abstract: The present invention relates to novel compounds, in particular, novel indazole that may be used as melanin concentrating hormone receptor ligands, methods of preparing such compounds, compositions containing such compounds, and methods of using such compounds to treat MCH related disorders.
Abstract: The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds.
Type:
Application
Filed:
November 14, 2007
Publication date:
June 19, 2008
Applicant:
Forest Laboratories Holdings Limited
Inventors:
Gian-Luca Araldi, Matthew Ronsheim, Melanie Ronsheim
Abstract: A method for treating autism comprising the step of administering an effective amount of Memantine and dextromethorphan or pharmaceutically acceptable derivatives and/or salts thereof.
Abstract: The present invention relates to imidazopyridine and imidazopyrimidine derivatives that act as cannabinoid receptor ligands, e.g., CB2 ligands. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Type:
Application
Filed:
August 27, 2007
Publication date:
March 6, 2008
Applicant:
Forest Laboratories Holdings Limited
Inventors:
Gian-Luca Araldi, Matthew Ronsheim, Nhut Diep
Abstract: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.